Wellington Management Group LLP Makes New $1.12 Million Investment in Omeros Corporation $OMER

Key Points

• Wellington Management Group LLP acquired 136,002 shares of Omeros Corporation, valued at approximately $1,118,000, indicating significant institutional interest in the biopharmaceutical company.
• Omeros reported a quarterly earnings per share of ($0.53), exceeding analysts' estimates, with revenue of $28.60 million, compared to a consensus estimate of $0.31 million.
• The average analyst rating for Omeros is a Moderate Buy, with a consensus price target of $18.00, reflecting a mixed outlook among analysts.

Wellington Management Group LLP purchased a new position in Omeros Corporation (NASDAQ:OMER - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 136,002 shares of the biopharmaceutical company's stock, valued at approximately $1,118,000. Wellington Management Group LLP owned 0.23% of Omeros at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its holdings in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 1,972 shares during the period. GAMMA Investing LLC grew its position in shares of Omeros by 14,486.3% during the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 7,388 shares in the last quarter. Harbour Investments Inc. grew its position in shares of Omeros by 51.9% during the 1st quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company's stock worth $76,000 after buying an additional 3,149 shares in the last quarter. Sowell Financial Services LLC purchased a new position in shares of Omeros during the first quarter valued at $88,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Omeros in the fourth quarter valued at about $124,000. Institutional investors own 48.79% of the company's stock.

Analysts Set New Price Targets

OMER has been the subject of a number of recent research reports. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research note on Friday, August 15th. HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Omeros in a report on Friday, June 27th. D. Boral Capital reissued a "buy" rating and issued a $36.00 price target on shares of Omeros in a research report on Wednesday. Finally, Wall Street Zen cut Omeros from a "hold" rating to a "sell" rating in a research note on Friday, June 27th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Omeros Price Performance

Omeros stock traded down $0.05 during midday trading on Thursday, reaching $4.14. The company's stock had a trading volume of 296,647 shares, compared to its average volume of 905,309. The stock has a market capitalization of $281.41 million, a P/E ratio of -1.96 and a beta of 2.37. The stock's 50-day simple moving average is $3.82 and its 200-day simple moving average is $5.38. Omeros Corporation has a 52-week low of $2.95 and a 52-week high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.02. The company had revenue of $28.60 million during the quarter, compared to analysts' expectations of $0.31 million. As a group, equities research analysts expect that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.